Fosun's AR1001 option, Bizengri's FDA expansion and BioMarin's Amicus integration

1️⃣ Fosun bought a global AR1001 option Fosun Pharma paid $60m for an option to expand rights to AriBio’s phase 3 Alzheimer’s drug AR1001 globally, with a further $80m due if it exercises after trial data.

💡 Why it matters Fosun is moving from regional commercialization partner to global call-option holder on a late-stage Alzheimer’s asset.

☕ Coffee talk Does Fosun want AR1001 data, or first refusal before Alzheimer’s optionality gets expensive?

2️⃣ Bizengri got a third FDA lane The FDA approved Partner Therapeutics’ Bizengri for adults with advanced NRG1 fusion-positive cholangiocarcinoma after prior systemic therapy.

💡 Why it matters This extends a rare precision-oncology asset beyond its 2024 pancreatic and NSCLC approvals, but on a very small biomarker-defined base.

☕ Coffee talk Is Bizengri still a niche bispecific, or is NRG1 becoming a small but ownable franchise?

3️⃣ BioMarin started trimming Amicus overlap BioMarin is cutting 58 roles at Amicus’ Princeton headquarters after closing the $4.8bn acquisition that brought in Galafold and Pombiliti plus Opfolda.

💡 Why it matters The thesis now shifts from rare-disease portfolio expansion to integration discipline and how much Amicus infrastructure BioMarin keeps.

☕ Coffee talk How much of Amicus did BioMarin really need once the marketed drugs were inside?